Company: AVCRF
Filing Date: 2025-06-16
Form Type: 20-F
Source: 0001641172-25-015266
Chunk: 27

Company: Avricore Health Inc.
Filing Date: 2025-06-16
Form: 20-F
Item: Item 7
Chunk 27
---
ITEM
7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

7. A.
Major Shareholders

As
of December 31, 2024, all shareholders have the same voting rights attached thereto as all other common shares of the Company. As of
December 31, 2024, the Company is not aware of any companies or individuals that hold more than 5% of the Issued and Outstanding Common
Shares.

7. A.1. a.
Holdings By Major Shareholders.

Refer
to ITEM #6. E and Table No. 10.

7. A.1. b.
Significant Changes in Major Shareholders’ Holdings.

- No
Disclosure Required -

7. A.1. c.
Different Voting Rights.

The
Company’s major shareholders do not have different voting rights.

7. A.2.
Canadian Share Ownership.

On
May 31, 2025, the Company’s shareholders’ list showed 101,289,664 common shares outstanding, an estimated 57 registered shareholders.
The Company’s transfer agent provides that there are 52 registered shareholders with Canadian addresses, 2 with United States addresses
and 3 foreign holders (Switzerland, Hong Kong and Bermuda).

7. A.3.
Control of the Company

The
Company is a publicly owned Canadian corporation, the shares of which are owned primarily by Canadian residents and other foreign residents.
The Company is not controlled by any foreign government or other person(s) except as described in ITEM #4. A., “ History and Development
of the Company”, and ITEM #6. E., “ Share Ownership”.

7. A.4.
Change of Control of Company Arrangements

- No
Disclosure Necessary -

  29  

7. B.
Related Party Transactions

Related
party transactions are described in Note 12 to the consolidated financial statements and are shown below. The remuneration of the Company’s
directors and other members of key management, being the President, Chief Executive Officer and Chief Financial Officer, who have the
authority and responsibility for planning, directing and controlling the activities of the Company, consist of the following:

                                                Year Ended                          Year Ended                          Year Ended                      
                                                December 31, 2024                   December 31, 2023                   December 31, 2022               
                                                $                                   $                                   $                               
  Accounts payable and accrued liabilities                                   -                                   -                                   -  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────